BridgeBio Pharma, Inc. · BBIO · Next earnings

BridgeBio Pharma, Inc. reports Tuesday, Feb 23, 2027

BBIO reports after market close with consensus EPS at $-0.61 and revenue at $310.8M. Last quarter: BridgeBio advances three launches while Attruby momentum holds

Reports After market close110 days awayDate estimated Healthcare

What the street expects

Consensus for the coming report
Consensus EPS $-0.61 Calendar consensus
Consensus revenue $310.8M Calendar consensus
Report date Feb 23, 2027 Tuesday, date estimated
Session After market close 110 days away

Where BBIO left off: FY2026 Q3

Full report

BridgeBio advances three launches while Attruby momentum holds

EPS surprise +22.5% Reported $-0.42 vs $-0.54
Revenue surprise +20.3% Reported $353.2M vs $293.5M
Stock move +6.0% Event window
Subsequent drift 0.0% Up to 20 sessions

Management's guidance sentiment remained maintained. The supplied analysis does not identify a new quantitative guidance change.

What to watch on the call

Carried forward from the last transcript

Risks management flagged

  • Regulatory delays or unfavorable outcomes for the three priority-review products.
  • Payer restrictions or 340B/ASP changes affecting Attruby pricing and reimbursement.
  • Competition from other TTR stabilizers and emerging silencers.
  • Execution risk from launching three products in a short period.
  • The citizen petition concerning infigratinib could create review or perception risk.

Questions analysts left open

  • The pace of Attruby growth in Q4 and 2027.
  • Capital allocation among organic investment, M&A, and share repurchases.
  • Launch ramp assumptions and performance metrics for BBP-418.
  • The effect of the infigratinib citizen petition on review timing and labeling.

Ask FN2 about BBIO next report

Transcript, numbers and history already loaded
What should I watch for in BBIO's next earnings report?How did BBIO guide last quarter, and is consensus above or below that?Give me the bull and bear case going into BBIO earnings.

Free account. Your question opens in FN2 with this report's transcript and numbers attached.

Get the BBIO recap when the next report posts

One email per quarter with the scorecard, the market reaction and what changed on the call. No account needed.

Recent BBIO quarters

All BBIO earnings
+6.0%FY2026 Q3-1.1%FY2026 Q2-0.1%FY2026 Q1-4.9%FY2025 Q3

Sources

  1. FN2 corporate events calendar, resolved from the earnings calendar feed
  2. FN2 earnings calendar analyst consensus
  3. Earnings call transcript analysis, FY2026 Q3

Methodology

The report date comes from FN2's resolved corporate-events calendar and is marked estimated until the company confirms it. Consensus figures are the calendar's latest analyst estimates for the fiscal period and are not an FN2 forecast.

Risks and open questions are carried forward verbatim from FN2's structured analysis of the previous earnings call. Missing values stay missing and are never estimated.

By FN2 Research · Updated . For educational purposes only; not investment advice.